Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Benedetta PellegrinoAndrea Herencia-RoperoAlba Llop-GuevaraFlaminia PedrettiAlejandro Moles-FernándezCristina ViaplanaGuillermo VillacampaMarta GuzmánOlga RodríguezJudit GruesoJose JiménezEnrique J ArenasAndrea DegasperiJoao M L DiasJosep V FormentLenka Oplustil O'ConnorOlivier DéasStefano CairoYinghui ZhouAntonino MusolinoCarlos CaldasSerena Nik-ZainalRobert B ClarkePaolo G NuciforoOrland DíezXavier Serres-CréixamsVicente PegMartín Espinosa-BravoTeresa MacarullaAna OakninJoaquin MateoJoaquín ArribasRodrigo DienstmannMeritxell Bellet-EzquerraMafalda OliveiraCristina SauraSara Gutiérrez-EnríquezJudith BalmañaVioleta SerraPublished in: Cancer research (2022)
This work demonstrates the high accuracy of a histopathology-based test based on the detection of RAD51 nuclear foci in predicting response to PARPi and cisplatin.